Progesterone formulations having a desirable pk profile
US-2024358839-A1 · Oct 31, 2024 · US
Progesterone solutions for increased bioavailability
US9011908B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9011908-B2 |
| Application number | US-75262910-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2010 |
| Priority date | Apr 6, 2009 |
| Publication date | Apr 21, 2015 |
| Grant date | Apr 21, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.
First claim
Opening claim text (preview).
We claim: 1. A hard or soft capsule comprising a shell and a liquid fill material, the liquid fill material comprising from about 7% to about 50% by weight of the fill of progesterone, wherein the progesterone is dissolved in a carrier comprising from about 60% to about 95% by weight of one or more pharmaceutically acceptable fatty acids; the fill comprising excipients enhancing dissolution of the progesterone consisting of (a) from about 1% to about 20% by weight of one or mo…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K9/4858Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9011908B2 cover?
- Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about…
- Who is the assignee on this patent?
- Liu Zhi, Gosangari Saujanya L, Toops Dana S, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K9/4858. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).